Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study.

"Authors' Disclosures J.M. Loree reports personal fees from Amgen, grants and personal fees from Ipsen, Novartis, and Bayer, and grants and non-financial support from Personalis, and non-financial support from SAGA Diagnostics, as well as personal fees from Merck and Eisai, and non-financial support from AstraZeneca outside the submitted work. C.J. Brown reports personal fees from Ethicon outside the submitted work. No disclosures were reported by the other authors."

"This research was funded by a Project Grant from the Canadian Institutes of Health Research, “Examining the epidemiology, treatment, and outcomes in young-onset colorectal cancer” (Funding reference number: PJT-159467), which was awarded to M.A. De Vera. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the article. We would like to acknowledge the following individuals for assisting with costing information: Dr. S. Lefresne, Dr. C. Duzenli, and Alison Giddings."